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The BCR-ABL1 fusion gene is a causative oncogene in chronic myeloid leukemia (CML) and 30--50 % of acute lymphoblastic leukemia cases \[[@CR1], [@CR2]\]. Although ABL tyrosine kinase inhibitors (ABL TKIs) such as imatinib, nilotinib, dasatinib, and bosutinib have improved CML treatment \[[@CR3]\], such therapies cannot cure patients with Philadelphia chromosome (Ph)-positive leukemia because of leukemia stem cells \[[@CR4]\]. Moreover, some patients develop BCR-ABL point mutations and become resistant to ABL TKI therapy \[[@CR5]\]. In particular, the ABL kinase domain mutation T315I is resistant to imatinib and second-generation ABL TKIs (e.g., nilotinib, dasatinib, and bosutinib). Accordingly, this mutation is often found in patients with TKI-resistant disease \[[@CR6]\]. A third-generation ABL TKI, ponatinib, and omacetaxine which is a semisynthetic form of homoharringtonine, was recently developed \[[@CR7]\]. Ponatinib is a potent oral tyrosine kinase inhibitor that affects both unmutated and mutated BCR-ABL \[[@CR8]\]; it is effective against T315I-mutant cells and has been approved for TKI-resistant or intolerant CML and Ph-positive ALL patients. Omacetaxine is approved for the treatment of chronic or accelerated-phase CML refractory to TKIs \[[@CR7]\].

Recently, the vascular endothelial growth factor receptor (VEGFR) inhibitor axitinib was found to exhibit anti-leukemic activity against T315I-mutant disease. In the comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS) trial \[[@CR9]\], axitinib improved progression-free survival (PFS) compared to sorafenib, which is an all-multikinase inhibitor that blocks angiogenesis targets \[[@CR10]\], in patients with advanced renal cell carcinoma (RCC). Axitinib was approved for the treatment of advanced RCC. Axitinib is an orally active and potent TKI of VEGFRs 1, 2, and 3 and inhibits BCR-ABL1, especially the T315I variant, via a distinct binding conformation \[[@CR11]\]. In this study, we investigated whether axitinib could suppress ponatinib-resistant compound-mutant cells harboring the T315I mutation. A 72-h axitinib treatment inhibited the growth of Ba/F3 T315I cells (Fig. [1a](#Fig1){ref-type="fig"}). Immunoblot analysis of axitinib-treated cells revealed dose-dependent decreases in BCR-ABL, the downstream molecule Crk-L, and ribosomal S6 protein phosphorylation and increases in caspase 3 and Poly (ADP-ribose) polymerase (PARP) activity (Fig. [1b](#Fig1){ref-type="fig"}, [c](#Fig1){ref-type="fig"}, [e](#Fig1){ref-type="fig"}). Ponatinib and axitinib also induced apoptosis, significantly increased caspase activity (Fig. [1d](#Fig1){ref-type="fig"}), and reduced Akt activity (Fig. [1f](#Fig1){ref-type="fig"}).Fig. 1Growth inhibition and cellular signaling following axitinib/ponatinib treatment in T315I-mutant and compound-mutant cells. **a** Ba/F3 T315I or Ba/F3 ponatinib-resistant (Ba/F3 ponatinib-R) cells were exposed to axitinib or ponatinib for 72 h at the indicated concentrations and subjected to quantitative cell proliferation analysis. Each result is presented as the mean percentage of proliferation relative to unexposed control cultures. \**P* \< 0.05 compared to T315I cells. **b** Ba/F3 T315I or Ba/F3 ponatinib-R cells were treated with ponatinib (10 nM) or axitinib (500 nM) for 24 h. Total cell extracts were examined via immunoblot analysis with anti-phospho ABL, phospho-Crk-L, phospho-S6, cleaved caspase 3, cleaved PARP, ABL, Crk-L, and β-actin antibodies. **c** Caspase activity was analyzed using an ApoAlert® Caspase-3 Colorimetric Assay Kit (Takara Bio Inc. Otsu, Shiga, Japan) according to the manufacturer's protocol. Data represent three independent sets of experiments. \**P* \< 0.05 compared to Ba/F3 T315I and Ba/F3 ponatinib-R cells. **d** Apoptosis in Ph-positive cell lines was assayed using a FITC Annexin V Apoptosis Detection Kit I™ (BD Pharmingen, San Jose, CA, USA). The experiments were performed in triplicate. **e** Ba/F3 T315I or Ba/F3 ponatinib-R cells were treated with axitinib at the indicated concentrations for 24 h. Total cell extracts were examined via immunoblot analysis with anti-phospho ABL, phospho-Crk-L, phospho-S6, cleaved caspase 3, cleaved PARP, ABL, Crk-L, and β-actin antibodies. **f** Akt activity was analyzed using a phospho-AKT 1/2/3 (Ser473) InstantOne™ enzyme-linked immunosorbent assay kit (Affymetrix, Cleveland, OH, USA) according to the manufacturer's protocol. Data represent three independent sets of experiments. \**P* \< 0.05 compared to Ba/F3 T315I and Ba/F3 ponatinib-R cells. **g**, **h** T315I-positive or compound-mutant primary cells were subjected to quantitative cell proliferation analysis after a 72-h exposure to axitinib or ponatinib. Each result is presented as the mean percentage of proliferation relative to unexposed control cultures. \**P* \< 0.05 compared to control. **i** T315I-positive or compound-mutant primary cells were treated with axitinib at the indicated concentrations for 24 h. Total cell extracts were examined via immunoblot analysis with anti-phospho-Crk-L, phospho-S6, cleaved PARP, and β-actin antibodies

In contrast, clinically available concentrations of axitinib did not inhibit the growth of ponatinib-resistant Ba/F3 cells (Fig. [1a](#Fig1){ref-type="fig"}). Immunoblot analysis revealed that BCR-ABL, Crk-L, and S6 kinase phosphorylation were not inhibited by axitinib or ponatinib (Fig. [1b](#Fig1){ref-type="fig"}, [e](#Fig1){ref-type="fig"}). Similarly, no increase in caspase activity or decrease in Akt activity was observed following axitinib treatment (Fig. [1c](#Fig1){ref-type="fig"}, [f](#Fig1){ref-type="fig"}), and neither ponatinib nor axitinib affected apoptosis in these cells (Fig. [1d](#Fig1){ref-type="fig"}).

We next evaluated primary T315I-mutant and ponatinib-resistant compound-mutant samples. Axitinib potently inhibited the growth of T315I-mutant primary cells in a dose-dependent manner (Fig. [1g](#Fig1){ref-type="fig"}). Immunoblot analysis further revealed reduced Crk-L and S6 kinase phosphorylation after axitinib or ponatinib treatment (Fig. [1i](#Fig1){ref-type="fig"}). In contrast, the growth of ponatinib-resistant primary cells was not affected by ponatinib or axitinib (Fig. [1h](#Fig1){ref-type="fig"}). Immunoblotting revealed that neither ponatinib nor axitinib affected the phosphorylation of Crk-L and S6 kinase in ponatinib-resistant cells (Fig. [1i](#Fig1){ref-type="fig"}).

In CML, ABL TKI resistance is frequently caused by ABL kinase domain mutations. The T315I mutation is resistant to all ABL TKIs except ponatinib. However, we previously described ponatinib-resistant cells resulting from a BCR-ABL compound mutation \[[@CR12]\]. Although axitinib, which is currently being investigated for efficacy in patients with Ph-positive T315I-mutant leukemia, induced apoptosis in T315I-mutant cells, it was ineffective against cells with a compound mutation including T315I. An alternative strategy will be required to improve the prognosis of patients with Ph-positive, BCR-ABL-mutant leukemia. Current evidence to direct the management of ABL TKI-resistant disease, particularly those harboring T315I and compound mutations, is limited. New molecular-targeted drugs and an understanding of ABL TKI resistance mechanisms are required to apply an appropriate therapeutic approach.
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